Market Research Life Sciences Market Research Diagnostics Market Research In Vitro Diagnostics Market Research Point-of-Care Market Research

Respiratory Panel Testing Market (Specimen Type: Viruses [Adenovirus, Severe Acute Respiratory Syndrome, RSV, Human Metapneumovirus, Rhinovirus/Enterovirus, Parainfluenza Virus, Flu A, Coronavirus, Flu B, HIN1 2009, and Others] and Bacteria [Mycoplasma Pn

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 305 Pages Transparency Market Research Pvt. Ltd. January, 2022 TNPR17063825
Best Price Guarantee
Price from $5,795
Length 305 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2022
SKU TNPR17063825

Respiratory Panel Testing Market (Specimen Type: Viruses [Adenovirus, Severe Acute Respiratory Syndrome, RSV, Human Metapneumovirus, Rhinovirus/Enterovirus, Parainfluenza Virus, Flu A, Coronavirus, Flu B, HIN1 2009, and Others] and Bacteria [Mycoplasma Pneumoniae, Chlamydophila Pneumonia, Bordetella Pertussis, and Bordetella Parapertussis]; Panel Type: Syndromic Full Multiplex Panel and Low Plex Panel; and End-user: Hospital Point-of-Care Testing, Ref Laboratories, Hospitals, and Others) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Europe and Middle East & Africa Respiratory Panel Testing Market – Scope of Report
TMR’s report on the respiratory panel testing market in Europe and Middle East & Africa studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the overall revenue of the respiratory panel testing market in Europe and Middle East & Africa for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the respiratory panel testing market in Europe and Middle East & Africa for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory panel testing market in Europe and Middle East & Africa.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the respiratory panel testing market in Europe and Middle East & Africa.

The report comprises an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the respiratory panel testing market in Europe and Middle East & Africa. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the respiratory panel testing market in Europe and Middle East & Africa. The next section of the respiratory panel testing market report highlights the USPs, which includes, COVID-19 pandemic impact on industry (value chain and short/mid/long term impact), and key industry events (mergers, acquisitions, partnerships, etc.) across Europe and Middle East & Africa.

The report delves into the competitive landscape of the respiratory panel testing market in Europe and Middle East & Africa. Key players operating in the respiratory panel testing market in Europe and Middle East & Africa have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the respiratory panel testing market in report.

Key Questions Answered in Europe and Middle East & Africa Respiratory Panel Testing Market Report
What are the sales/revenue generated by respiratory panel testing across Europe and Middle East & Africa during the forecast period?
What are the key trends in the respiratory panel testing market in Europe and Middle East & Africa?
What are the major drivers, restraints, opportunities, and threats in the market?
Which segment will have the highest revenue by 2031 and which segment will grow at the highest CAGR during the forecast period?
Which region is set to expand at the fastest CAGR during the forecast period?
Strengths and weaknesses of major players (2019–2020)
Competitive analysis of major players (2019–2020)
Europe and Middle East & Africa Respiratory Panel Testing Market – Research Objectives and Research Approach
The comprehensive report on the respiratory panel testing market in Europe and Middle East & Africa begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the respiratory panel testing market in Europe and Middle East & Africa. It is followed by market introduction, market dynamics, and an overview of the respiratory panel testing market in Europe and Middle East & Africa, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the respiratory panel testing market in Europe and Middle East & Africa.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key product manufacturers has been mapped to ascertain the size of the respiratory panel testing market in Europe and Middle East & Africa in terms of value. The forecast presented here assesses the total revenue generated in the respiratory panel testing market in Europe and Middle East & Africa. In order to provide an accurate forecast, we initiated by sizing up the current respiratory panel testing market in Europe and Middle East & Africa with the help of the parent market.

The report analyzes the respiratory panel testing market in Europe and Middle East & Africa in terms of specimen type, panel type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the respiratory panel testing market in Europe and Middle East & Africa.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Respiratory Panel Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, 2018–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Specimen Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
6.3.1. Viruses
6.3.1.1. Adenovirus
6.3.1.2. Severe Acute Respiratory Syndrome
6.3.1.3. RSV
6.3.1.4. Human Metapneumovirus
6.3.1.5. Rhinovirus/Enterovirus
6.3.1.6. Parainfluenza Virus
6.3.1.7. Flu A
6.3.1.8. Others
6.3.2. Bacteria
6.3.2.1. Mycoplasma Pneumoniae
6.3.2.2. Chlamydophila Pneumonia
6.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type
7. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Panel Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Panel Type
8. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
8.3.1. Hospital Point-of-Care testing
8.3.2. Reference Labs
8.3.3. Hospitals
8.3.4. Others
8.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by End-user
9. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region
9.2.1. Europe
9.2.2. Middle East & Africa
9.3. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Country/Region
10. Europe Respiratory Panel Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
10.2.1. Viruses
10.2.1.1. Adenovirus
10.2.1.2. Severe Acute Respiratory Syndrome
10.2.1.3. RSV
10.2.1.4. Human Metapneumovirus
10.2.1.5. Rhinovirus/Enterovirus
10.2.1.6. Parainfluenza Virus
10.2.1.7. Flu A
10.2.1.8. Others
10.2.2. Bacteria
10.2.2.1. Mycoplasma Pneumoniae
10.2.2.2. Chlamydophila Pneumonia
10.3. Market Value Forecast, by Panel Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospital Point-of-Care testing
10.4.2. Ref Laboratories
10.4.3. Hospitals
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.1.1.1. Viruses
10.5.1.1.1.1. Adenovirus
10.5.1.1.1.2. Severe Acute Respiratory Syndrome
10.5.1.1.1.3. RSV
10.5.1.1.1.4. Human Metapneumovirus
10.5.1.1.1.5. Rhinovirus/Enterovirus
10.5.1.1.1.6. Parainfluenza Virus
10.5.1.1.1.7. Flu A
10.5.1.1.1.8. Others
10.5.1.1.2. Bacteria
10.5.1.1.2.1. Mycoplasma Pneumoniae
10.5.1.1.2.2. Chlamydophila Pneumonia
10.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospital Point-of-Care testing
10.5.1.3.2. Ref Laboratories
10.5.1.3.3. Hospitals
10.5.1.3.4. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.2.1.1. Viruses
10.5.2.1.1.1. Adenovirus
10.5.2.1.1.2. Severe Acute Respiratory Syndrome
10.5.2.1.1.3. RSV
10.5.2.1.1.4. Human Metapneumovirus
10.5.2.1.1.5. Rhinovirus/Enterovirus
10.5.2.1.1.6. Parainfluenza Virus
10.5.2.1.1.7. Flu A
10.5.2.1.1.8. Others
10.5.2.1.2. Bacteria
10.5.2.1.2.1. Mycoplasma Pneumoniae
10.5.2.1.2.2. Chlamydophila Pneumonia
10.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospital Point-of-Care testing
10.5.2.3.2. Ref Laboratories
10.5.2.3.3. Hospitals
10.5.2.3.4. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.3.1.1. Viruses
10.5.3.1.1.1. Adenovirus
10.5.3.1.1.2. Severe Acute Respiratory Syndrome
10.5.3.1.1.3. RSV
10.5.3.1.1.4. Human Metapneumovirus
10.5.3.1.1.5. Rhinovirus/Enterovirus
10.5.3.1.1.6. Parainfluenza Virus
10.5.3.1.1.7. Flu A
10.5.3.1.1.8. Others
10.5.3.1.2. Bacteria
10.5.3.1.2.1. Mycoplasma Pneumoniae
10.5.3.1.2.2. Chlamydophila Pneumonia
10.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospital Point-of-Care testing
10.5.3.3.2. Ref Laboratories
10.5.3.3.3. Hospitals
10.5.3.3.4. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.4.1.1. Viruses
10.5.4.1.1.1. Adenovirus
10.5.4.1.1.2. Severe Acute Respiratory Syndrome
10.5.4.1.1.3. RSV
10.5.4.1.1.4. Human Metapneumovirus
10.5.4.1.1.5. Rhinovirus/Enterovirus
10.5.4.1.1.6. Parainfluenza Virus
10.5.4.1.1.7. Flu A
10.5.4.1.1.8. Others
10.5.4.1.2. Bacteria
10.5.4.1.2.1. Mycoplasma Pneumoniae
10.5.4.1.2.2. Chlamydophila Pneumonia
10.5.4.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospital Point-of-Care testing
10.5.4.3.2. Ref Laboratories
10.5.4.3.3. Hospitals
10.5.4.3.4. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.5.1.1. Viruses
10.5.5.1.1.1. Adenovirus
10.5.5.1.1.2. Severe Acute Respiratory Syndrome
10.5.5.1.1.3. RSV
10.5.5.1.1.4. Human Metapneumovirus
10.5.5.1.1.5. Rhinovirus/Enterovirus
10.5.5.1.1.6. Parainfluenza Virus
10.5.5.1.1.7. Flu A
10.5.5.1.1.8. Others
10.5.5.1.2. Bacteria
10.5.5.1.2.1. Mycoplasma Pneumoniae
10.5.5.1.2.2. Chlamydophila Pneumonia
10.5.5.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospital Point-of-Care testing
10.5.5.3.2. Ref Laboratories
10.5.5.3.3. Hospitals
10.5.5.3.4. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.6.1.1. Viruses
10.5.6.1.1.1. Adenovirus
10.5.6.1.1.2. Severe Acute Respiratory Syndrome
10.5.6.1.1.3. RSV
10.5.6.1.1.4. Human Metapneumovirus
10.5.6.1.1.5. Rhinovirus/Enterovirus
10.5.6.1.1.6. Parainfluenza Virus
10.5.6.1.1.7. Flu A
10.5.6.1.1.8. Others
10.5.6.1.2. Bacteria
10.5.6.1.2.1. Mycoplasma Pneumoniae
10.5.6.1.2.2. Chlamydophila Pneumonia
10.5.6.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospital Point-of-Care testing
10.5.6.3.2. Ref Laboratories
10.5.6.3.3. Hospitals
10.5.6.3.4. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.7.1.1. Viruses
10.5.7.1.1.1. Adenovirus
10.5.7.1.1.2. Severe Acute Respiratory Syndrome
10.5.7.1.1.3. RSV
10.5.7.1.1.4. Human Metapneumovirus
10.5.7.1.1.5. Rhinovirus/Enterovirus
10.5.7.1.1.6. Parainfluenza Virus
10.5.7.1.1.7. Flu A
10.5.7.1.1.8. Others
10.5.7.1.2. Bacteria
10.5.7.1.2.1. Mycoplasma Pneumoniae
10.5.7.1.2.2. Chlamydophila Pneumonia
10.5.7.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospital Point-of-Care testing
10.5.7.3.2. Ref Laboratories
10.5.7.3.3. Hospitals
10.5.7.3.4. Others
10.5.8. Sweden
10.5.8.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.8.1.1. Viruses
10.5.8.1.1.1. Adenovirus
10.5.8.1.1.2. Severe Acute Respiratory Syndrome
10.5.8.1.1.3. RSV
10.5.8.1.1.4. Human Metapneumovirus
10.5.8.1.1.5. Rhinovirus/Enterovirus
10.5.8.1.1.6. Parainfluenza Virus
10.5.8.1.1.7. Flu A
10.5.8.1.1.8. Others
10.5.8.1.2. Bacteria
10.5.8.1.2.1. Mycoplasma Pneumoniae
10.5.8.1.2.2. Chlamydophila Pneumonia
10.5.8.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospital Point-of-Care testing
10.5.8.3.2. Ref Laboratories
10.5.8.3.3. Hospitals
10.5.8.3.4. Others
10.5.9. Denmark
10.5.9.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.9.1.1. Viruses
10.5.9.1.1.1. Adenovirus
10.5.9.1.1.2. Severe Acute Respiratory Syndrome
10.5.9.1.1.3. RSV
10.5.9.1.1.4. Human Metapneumovirus
10.5.9.1.1.5. Rhinovirus/Enterovirus
10.5.9.1.1.6. Parainfluenza Virus
10.5.9.1.1.7. Flu A
10.5.9.1.1.8. Others
10.5.9.1.2. Bacteria
10.5.9.1.2.1. Mycoplasma Pneumoniae
10.5.9.1.2.2. Chlamydophila Pneumonia
10.5.9.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017–2031
10.5.9.3.1. Hospital Point-of-Care testing
10.5.9.3.2. Ref Laboratories
10.5.9.3.3. Hospitals
10.5.9.3.4. Others
10.5.10. Finland
10.5.10.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.10.1.1. Viruses
10.5.10.1.1.1. Adenovirus
10.5.10.1.1.2. Severe Acute Respiratory Syndrome
10.5.10.1.1.3. RSV
10.5.10.1.1.4. Human Metapneumovirus
10.5.10.1.1.5. Rhinovirus/Enterovirus
10.5.10.1.1.6. Parainfluenza Virus
10.5.10.1.1.7. Flu A
10.5.10.1.1.8. Others
10.5.10.1.2. Bacteria
10.5.10.1.2.1. Mycoplasma Pneumoniae
10.5.10.1.2.2. Chlamydophila Pneumonia
10.5.10.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospital Point-of-Care testing
10.5.10.3.2. Ref Laboratories
10.5.10.3.3. Hospitals
10.5.10.3.4. Others
10.5.11. Norway
10.5.11.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.11.1.1. Viruses
10.5.11.1.1.1. Adenovirus
10.5.11.1.1.2. Severe Acute Respiratory Syndrome
10.5.11.1.1.3. RSV
10.5.11.1.1.4. Human Metapneumovirus
10.5.11.1.1.5. Rhinovirus/Enterovirus
10.5.11.1.1.6. Parainfluenza Virus
10.5.11.1.1.7. Flu A
10.5.11.1.1.8. Others
10.5.11.1.2. Bacteria
10.5.11.1.2.1. Mycoplasma Pneumoniae
10.5.11.1.2.2. Chlamydophila Pneumonia
10.5.11.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospital Point-of-Care testing
10.5.11.3.2. Ref Laboratories
10.5.11.3.3. Hospitals
10.5.11.3.4. Others
10.5.12. Switzerland
10.5.12.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.12.1.1. Viruses
10.5.12.1.1.1. Adenovirus
10.5.12.1.1.2. Severe Acute Respiratory Syndrome
10.5.12.1.1.3. RSV
10.5.12.1.1.4. Human Metapneumovirus
10.5.12.1.1.5. Rhinovirus/Enterovirus
10.5.12.1.1.6. Parainfluenza Virus
10.5.12.1.1.7. Flu A
10.5.12.1.1.8. Others
10.5.12.1.2. Bacteria
10.5.12.1.2.1. Mycoplasma Pneumoniae
10.5.12.1.2.2. Chlamydophila Pneumonia
10.5.12.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospital Point-of-Care testing
10.5.12.3.2. Ref Laboratories
10.5.12.3.3. Hospitals
10.5.12.3.4. Others
10.5.13. Austria
10.5.13.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.13.1.1. Viruses
10.5.13.1.1.1. Adenovirus
10.5.13.1.1.2. Severe Acute Respiratory Syndrome
10.5.13.1.1.3. RSV
10.5.13.1.1.4. Human Metapneumovirus
10.5.13.1.1.5. Rhinovirus/Enterovirus
10.5.13.1.1.6. Parainfluenza Virus
10.5.13.1.1.7. Flu A
10.5.13.1.1.8. Others
10.5.13.1.2. Bacteria
10.5.13.1.2.1. Mycoplasma Pneumoniae
10.5.13.1.2.2. Chlamydophila Pneumonia
10.5.13.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospital Point-of-Care testing
10.5.13.3.2. Ref Laboratories
10.5.13.3.3. Hospitals
10.5.13.3.4. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.14.1.1. Viruses
10.5.14.1.1.1. Adenovirus
10.5.14.1.1.2. Severe Acute Respiratory Syndrome
10.5.14.1.1.3. RSV
10.5.14.1.1.4. Human Metapneumovirus
10.5.14.1.1.5. Rhinovirus/Enterovirus
10.5.14.1.1.6. Parainfluenza Virus
10.5.14.1.1.7. Flu A
10.5.14.1.1.8. Others
10.5.14.1.2. Bacteria
10.5.14.1.2.1. Mycoplasma Pneumoniae
10.5.14.1.2.2. Chlamydophila Pneumonia
10.5.14.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospital Point-of-Care testing
10.5.14.3.2. Ref Laboratories
10.5.14.3.3. Hospitals
10.5.14.3.4. Others
10.6. Market Attractiveness Analysis
10.6.1. By Specimen Type
10.6.2. By Panel Type
10.6.3. By End-user
10.6.4. By Country/Sub-region
11. Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
11.2.1. Viruses
11.2.1.1. Adenovirus
11.2.1.2. Severe Acute Respiratory Syndrome
11.2.1.3. RSV
11.2.1.4. Human Metapneumovirus
11.2.1.5. Rhinovirus/Enterovirus
11.2.1.6. Parainfluenza Virus
11.2.1.7. Flu A
11.2.1.8. Others
11.2.2. Bacteria
11.2.2.1. Mycoplasma Pneumoniae
11.2.2.2. Chlamydophila Pneumonia
11.3. Market Value Forecast, by Panel Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospital Point-of-Care testing
11.4.2. Ref Laboratories
11.4.3. Hospitals
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.1.1.1. Viruses
11.5.1.1.1.1. Adenovirus
11.5.1.1.1.2. Severe Acute Respiratory Syndrome
11.5.1.1.1.3. RSV
11.5.1.1.1.4. Human Metapneumovirus
11.5.1.1.1.5. Rhinovirus/Enterovirus
11.5.1.1.1.6. Parainfluenza Virus
11.5.1.1.1.7. Flu A
11.5.1.1.1.8. Others
11.5.1.1.2. Bacteria
11.5.1.1.2.1. Mycoplasma Pneumoniae
11.5.1.1.2.2. Chlamydophila Pneumonia
11.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospital Point-of-Care testing
11.5.1.3.2. Ref Laboratories
11.5.1.3.3. Hospitals
11.5.1.3.4. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.2.1.1. Viruses
11.5.2.1.1.1. Adenovirus
11.5.2.1.1.2. Severe Acute Respiratory Syndrome
11.5.2.1.1.3. RSV
11.5.2.1.1.4. Human Metapneumovirus
11.5.2.1.1.5. Rhinovirus/Enterovirus
11.5.2.1.1.6. Parainfluenza Virus
11.5.2.1.1.7. Flu A
11.5.2.1.1.8. Others
11.5.2.1.2. Bacteria
11.5.2.1.2.1. Mycoplasma Pneumoniae
11.5.2.1.2.2. Chlamydophila Pneumonia
11.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospital Point-of-Care testing
11.5.2.3.2. Ref Laboratories
11.5.2.3.3. Hospitals
11.5.2.3.4. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.3.1.1. Viruses
11.5.3.1.1.1. Adenovirus
11.5.3.1.1.2. Severe Acute Respiratory Syndrome
11.5.3.1.1.3. RSV
11.5.3.1.1.4. Human Metapneumovirus
11.5.3.1.1.5. Rhinovirus/Enterovirus
11.5.3.1.1.6. Parainfluenza Virus
11.5.3.1.1.7. Flu A
11.5.3.1.1.8. Others
11.5.3.1.2. Bacteria
11.5.3.1.2.1. Mycoplasma Pneumoniae
11.5.3.1.2.2. Chlamydophila Pneumonia
11.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospital Point-of-Care testing
11.5.3.3.2. Ref Laboratories
11.5.3.3.3. Hospitals
11.5.3.3.4. Others
12. Competitive Landscape
12.1. Market Player –Competition Matrix (By Tier and Size of companies)
12.2. Company Profiles (2020)
12.2.1. F. Hoffmann-La Roche Ltd.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. Financial Overview
12.2.1.4. Strategic Overview
12.2.1.5. SWOT Analysis
12.2.2. bioMerieux SA
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. Financial Overview
12.2.2.4. Strategic Overview
12.2.2.5. SWOT Analysis
12.2.3. Medline Industries, Inc.
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. Strategic Overview
12.2.3.4. SWOT Analysis
12.2.4. Becton, Dickinson & Company
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. Financial Overview
12.2.4.4. Strategic Overview
12.2.4.5. SWOT Analysis
12.2.5. altona Diagnostics GmbH
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. Strategic Overview
12.2.5.4. SWOT Analysis
12.2.6. CerTest Biotec S.L.
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. Strategic Overview
12.2.6.4. SWOT Analysis
12.2.7. Anatolia Geneworks
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. Strategic Overview
12.2.7.4. SWOT Analysis
12.2.8. Seegene, Inc.
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. Strategic Overview
12.2.8.4. SWOT Analysis
12.2.9. DiaSorin S.p.A. (Luminex)
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. Financial Overview
12.2.9.4. Strategic Overview
12.2.9.5. SWOT Analysis
12.2.10. QIAGEN
12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.10.2. Product Portfolio
12.2.10.3. Financial Overview
12.2.10.4. Strategic Overview
12.2.10.5. SWOT Analysis
12.2.11. Biocartis
12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.11.2. Product Portfolio
12.2.11.3. Strategic Overview
12.2.11.4. SWOT Analysis

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings